Are you on the hunt for some big returns for your investment portfolio?
Well, if you are, then it could pay to listen to what analysts are saying about the ASX 200 shares in this article.
That's because if everything goes to plan, they believe that these shares could deliver double-digit returns for investors over the next 12 months.
Let's see which shares they are recommending to clients right now:s
Image source: Getty Images
Neuren Pharmaceuticals Ltd (ASX: NEU)
The first ASX 200 share that could be destined to rise strongly from current levels is Neuren Pharmaceuticals.
It is a pharmaceuticals company that is developing new therapies for highly debilitating neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.
The team at Macquarie is very positive on the company's outlook and sees value in its shares. Particularly given that the market only seems to be pricing North American Daybue sales into its current valuation. It explains:
Current valuation offers favourable risk-reward. We believe DAYBUE in NA is driving most of current share price, with further upside from ROW/ pipeline. Its strong cash position enables pipeline acceleration, potentially providing significant long-term upside if approved.
Catalysts: 1) NEU's 1H25 result, Acadia's 2Q25 result. 2) PMS trial commencement (expected 2H25E). 3) DAYBUE Canada launch. 4) DAYBUE EMA approval (potentially 1Q26E).
Macquarie currently has an outperform rating and $18.60 price target on its shares. Based on its current share price of $16.63, this implies potential upside of almost 12% for investors.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another ASX 200 stock that could deliver big returns is Telix Pharmaceuticals.
It is a rapidly growing biotechnology company focused on theranostics using targeted radiation to both image and treat cancers.
Its flagship product, Illuccix, is already approved and generating revenue in the US, and Telix continues to build out a growing pipeline of potential treatments across a range of cancers and rare diseases.
Bell Potter is a big fan of the company and feels that recent share price weakness has created a buying opportunity for investors. Particularly given the potential of its yet to be approved Zircaix product. It said:
Zircaix is well-positioned to contribute to TLX's revenue from FY2026. Approval in August would allow the company 4 months to establish a new HCPCS code and Pass Through Pricing from 1 Jan 2026. In the absence of reimbursement, FY25 revenues (from Zircaix) are likely to be negligible. Telix's FY2025 guidance of AU$1.18–$1.23bn excludes any revenues contribution from Zircaix.
Bell Potter has a buy rating and $34.00 price target on its shares. This implies potential upside of over 60% from current levels.
